Figure 4

Normalization of IL-1β enhanced glycosaminoglycan release from human cartilage explants by RNI 249. Treatment of human cartilage explants (n = 6) with IL-1β (5 ng/ml) results in the release of glycosaminoglycans (GAG) into the media. Administration of RNI 249 produced a dose-dependent decrease of IL-1β induced GAG release that was significant at the 10 μg/ml (R10, * P < 0.05) and 50 μg/ml (** P < 0.01) concentrations. The level of GAG release from control, untreated explants was indistinguishable from those explants treated with IL-1β + RNI 249 (50 μg/ml).